Researchers at Sweden's Karolinska Institutet and the University of Oulu in Finland have elucidated gene regulatory mechanisms that can explain how known genetic variants influence prostate cancer risk. The findings, published ...
Mar 7, 2016
0
24
(HealthDay)—Hormone therapy for prostate cancer might dramatically increase a man's risk of developing Alzheimer's disease, a large-scale analysis of health data suggests.
Dec 8, 2015
0
59
Scientists have gained a key insight into how prostate tumors get their start - not by rewriting the normal DNA code, but by reprogramming the master regulator of genes in prostate cells to drive malignant growth.
Oct 12, 2015
0
103
Researchers at University of California, San Diego School of Medicine have identified the mechanism by which a rare, inherited neurodegenerative disease causes often crippling muscle weakness in men, in addition to reduced ...
Aug 10, 2014
0
0
Prostate cancer becomes deadly when anti-hormone treatments stop working. Now a new study suggests a way to block the hormones at their entrance.
Apr 23, 2014
0
0
(Medical Xpress)—Several fertility clinics across the country are beginning to administer testosterone, either through a patch or a gel on the skin, to increase the number of eggs produced by certain women undergoing in ...
Mar 4, 2014
0
0
A team of researchers from UC Davis, UC San Diego and other institutions has identified a key mechanism behind aggressive prostate cancer. Published on August 14, 2013 in Nature, the study shows that two long non-coding RNAs ...
Aug 14, 2013
0
0
Researchers have identified a sub-group of cells that could contribute to prostate cancer recurrence, opening up new ways to treat the disease, which claims more than 3000 lives a year in Australia.
May 29, 2013
0
0
Dr. Jung-Mo Ahn, associate professor of chemistry at The University of Texas at Dallas, has designed and synthesized a novel small molecule that might become a large weapon in the fight against prostate cancer.
May 28, 2013
0
5
A new study on prostate cancer describes a novel class of drugs developed by UT Southwestern Medical Center researchers that interrupts critical signaling needed for prostate cancer cells to grow.
May 28, 2013
0
0
